These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 27717529)

  • 1. Individualizing surgical treatment based on tumour response following neoadjuvant therapy in T4 primary rectal cancer.
    Denost Q; Kontovounisios C; Rasheed S; Chevalier R; Brasio R; Capdepont M; Rullier E; Tekkis PP
    Eur J Surg Oncol; 2017 Jan; 43(1):92-99. PubMed ID: 27717529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.
    Belluco C; Forlin M; Olivieri M; Cannizzaro R; Canzonieri V; Buonadonna A; Bidoli E; Matrone F; Bertola G; De Paoli A
    Ann Surg Oncol; 2016 Dec; 23(13):4302-4309. PubMed ID: 27489059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efforts to improve local control in rectal cancer compromise survival by the potential morbidity of optimal mesorectal excision.
    Laurent C; Nobili S; Rullier A; Vendrely V; Saric J; Rullier E
    J Am Coll Surg; 2006 Nov; 203(5):684-91. PubMed ID: 17084330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
    Rullier E; Rouanet P; Tuech JJ; Valverde A; Lelong B; Rivoire M; Faucheron JL; Jafari M; Portier G; Meunier B; Sileznieff I; Prudhomme M; Marchal F; Pocard M; Pezet D; Rullier A; Vendrely V; Denost Q; Asselineau J; Doussau A
    Lancet; 2017 Jul; 390(10093):469-479. PubMed ID: 28601342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.
    Jung SM; Yu CS; Park IJ; Kim TW; Kim JH; Yoon YS; Lim SB; Kim JC
    Medicine (Baltimore); 2016 May; 95(20):e3718. PubMed ID: 27196490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer.
    Kulu Y; Tarantino I; Billeter AT; Diener MK; Schmidt T; Büchler MW; Ulrich A
    Ann Surg Oncol; 2016 Jan; 23(1):106-13. PubMed ID: 26305025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients.
    Law WL; Chu KW
    Ann Surg; 2004 Aug; 240(2):260-8. PubMed ID: 15273550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and patterns of failure after surgery for T4 rectal cancer in the beyond total mesorectal excision era.
    Peacock O; Waters PS; Bressel M; Lynch AC; Wakeman C; Eglinton T; Koh CE; Lee PJ; Austin KK; Warrier SK; Solomon MJ; Frizelle FA; Heriot AG
    Br J Surg; 2019 Nov; 106(12):1685-1696. PubMed ID: 31339561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure?
    Rahbari NN; Ulrich AB; Bruckner T; Münter M; Nickles A; Contin P; Löffler T; Reissfelder C; Koch M; Büchler MW; Weitz J
    Ann Surg; 2011 Mar; 253(3):522-33. PubMed ID: 21209587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
    Kim JC; Takahashi K; Yu CS; Kim HC; Kim TW; Ryu MH; Kim JH; Mori T
    Ann Surg; 2007 Nov; 246(5):754-62. PubMed ID: 17968166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tailored Treatment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Preliminary Results of the French Phase II Multicenter GRECCAR4 Trial.
    Rouanet P; Rullier E; Lelong B; Maingon P; Tuech JJ; Pezet D; Castan F; Nougaret S;
    Dis Colon Rectum; 2017 Jul; 60(7):653-663. PubMed ID: 28594714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
    Sclafani F; Brown G; Cunningham D; Rao S; Tekkis P; Tait D; Morano F; Baratelli C; Kalaitzaki E; Rasheed S; Watkins D; Starling N; Wotherspoon A; Chau I
    Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local excision after neoadjuvant chemoradiotherapy versus total mesorectal excision: a case-matched study in 110 selected high-risk patients with rectal cancer.
    Calmels M; Collard MK; Cazelles A; Frontali A; Maggiori L; Panis Y
    Colorectal Dis; 2020 Dec; 22(12):1999-2007. PubMed ID: 32813899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total Mesorectal Excision Versus Local Excision After Favorable Response to Preoperative Chemoradiotherapy in "Early" Clinical T3 Rectal Cancer: A Propensity Score Analysis.
    Shin YS; Yu CS; Park JH; Kim JC; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Yoon SM; Joo JH; Kim JH
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):136-144. PubMed ID: 28816139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
    Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy.
    Ogura A; Akiyoshi T; Nagasaki T; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Kuroyanagi H
    World J Surg; 2017 Mar; 41(3):868-875. PubMed ID: 27730352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors that influence the adequacy of total mesorectal excision for rectal cancer.
    Jeyarajah S; Sutton CD; Miller AS; Hemingway D;
    Colorectal Dis; 2007 Nov; 9(9):808-15. PubMed ID: 17441969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically Node Negative, Pathologically Node Positive Rectal Cancer Patients Who Did Not Receive Neoadjuvant Therapy.
    Akeel N; Lan N; Stocchi L; Costedio MM; Dietz DW; Gorgun E; Kalady MF; Karagkounis G; Kessler H; Remzi FH
    J Gastrointest Surg; 2017 Jan; 21(1):49-55. PubMed ID: 27796635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.